about
Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines.Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics.The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.Autoimmune and Atopic Disorders and Risk of Classical Hodgkin LymphomaThe potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma.Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysisReproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case-control study.Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy.Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.Novel treatment concepts in Hodgkin lymphoma.Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma.Expression of mast cell tryptases in Hodgkin and Reed-Sternberg (HRS) cells.Risk of disability pension in patients following rectal cancer treatment and surgery.Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.Work Loss Duration and Predictors Following Rectal Cancer Treatment among Patients with and without Prediagnostic Work Loss.Risk of lymphoid neoplasms in a Swedish population-based cohort of 337,437 patients undergoing appendectomy.The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children.A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma.Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment.Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study.Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's lymphoma--a population-based study.The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence.Erratum to: Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study.Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma - a Swedish lymphoma register studyHigh proportions of PD-1 and PD-L1 leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcomeIL-9 expression contributes to the cellular composition in Hodgkin lymphomaAngiogenesis and mast cells in Hodgkin lymphomaNo excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapyComorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort studyDistribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and DenmarkCancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register studyHigh prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study
P50
Q33934710-D4249ABF-A552-4893-B3FB-9864D7A4408DQ34672857-56E58E4A-662F-46D1-8E76-60F8705AF6CFQ35832484-B5742ECF-DA63-495E-84EB-D9089EAB4E3AQ36089344-4FCDA919-5B0F-49E3-B209-FD1DA924CF38Q36957013-9529E4EB-9751-482F-8B92-15618E49CD62Q37311256-17A09C34-738B-453E-A676-DBDCCBF527B3Q37457202-C5FF8A07-37B7-4DBC-9181-B01098545CE0Q38403661-613D9F56-98B0-43DB-8F8E-1DBC2D095E54Q38931871-CAB06FC5-84EC-4CBE-AEB0-5FEBC2FEA03BQ39043082-0698D948-EAFA-4F13-A5DA-038959275C81Q40025019-2D7192BA-B395-4637-8BA4-9508191B5896Q40049855-8C31E9C1-B2C6-46A1-96EB-AE23F0271867Q40690819-5DAAA284-EB4A-4661-8B26-6D029724A42EQ40703339-6BAF7D29-545F-4C65-9DBF-BDCD61318E9FQ40745676-55D1581F-40AA-4E0E-B522-83DC771CCF97Q40877010-8A9B7265-0DAC-49EE-A92E-94BED3C3C533Q40912853-D5A7C58C-2F45-45B5-A1C1-17B4992BA07CQ40982679-9D88F4DA-09DB-427A-99C1-EE6323FDFB95Q41126169-A76C7C13-165C-43B6-9844-B416815C778FQ41414915-29066998-0B48-4B43-A399-EB8DC2679F00Q44227245-B1B18C4C-9C3F-46BA-86CE-9D9CD11EB23FQ51748246-38670CEE-A5D5-4697-85C5-C390600B6106Q53209425-32981860-87D5-41FC-8168-4116D1891292Q58109035-38FDFCB6-D554-4AAC-8827-3C7524901D4AQ59468458-BA384839-0161-496B-9696-9308EDA6734BQ62082808-60A652D5-504E-442B-8079-793F54E27E99Q62082817-96302C6D-B23C-4972-A4FA-9803B689584FQ90708594-3F81EEAF-1D6F-44C9-AE4C-D79F3CDFDD1AQ91265534-EDA0FB70-0368-46BC-A16F-35DC51AF007EQ91544829-D0233AEC-F390-4776-A85E-2184C3165A19Q92515705-D05E5289-9858-4760-9B65-B91FDC5012F5Q96219488-B61CC454-B0CE-4716-9022-F19894CF480D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ingrid Glimelius
@ast
Ingrid Glimelius
@en
Ingrid Glimelius
@es
Ingrid Glimelius
@nl
Ingrid Glimelius
@sl
type
label
Ingrid Glimelius
@ast
Ingrid Glimelius
@en
Ingrid Glimelius
@es
Ingrid Glimelius
@nl
Ingrid Glimelius
@sl
prefLabel
Ingrid Glimelius
@ast
Ingrid Glimelius
@en
Ingrid Glimelius
@es
Ingrid Glimelius
@nl
Ingrid Glimelius
@sl
P1053
Q-1325-2015
P106
P21
P31
P3829
P496
0000-0001-6158-3041